Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Harrow, Inc. (HROW) Guidance & Earnings Results

On 2026-08-10 Harrow, Inc. reaffirmed guidance: "Revenue $350M-$365M, Adj. EBITDA $80M-$100M for…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HROWHarrow, Inc.Follow HROW — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
1.1B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
16 Nov, in 23 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
10 Aug 26ReaffirmedRevenue $350M-$365M, Adj. EBITDA $80M-$100M for FY2026 · full year
11 May 26ReaffirmedFull-year 2026 revenue $350M-$365M, Adjusted EBITDA $80M-$100M, VEVYE >$100M · full year
2 Feb 26ReaffirmedRevenue guidance $270M-$280M for FY2025 · full year
11 Aug 25RaisedVEVYE revenue of $60 million or higher for the balance of the year (H2 2025) · full year

Harrow, Inc. — questions

What guidance did Harrow, Inc. give?
On 2026-08-10: "Revenue $350M-$365M, Adj. EBITDA $80M-$100M for FY2026"
When does Harrow, Inc. report earnings?
Harrow, Inc.'s next earnings report is expected on 2026-11-16.

Every figure on this page comes from Harrow, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.